The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Signs of an inflammatory process, in particular increased pro-inflammatory cytokines and increased levels of prostaglandine E(2) (PGE(2)), have repeatedly been described in major depression (MD). As cyclooxygenase-2 (COX-2) inhibitors inhibit the PGE(2) production and the production of pro-inflammatory cytokines, we performed a therapeutic trial with the COX-2 inhibitor celecoxib. In a prospective, double-blind, add-on study, 40 patients suffering from an acute depressive episode were randomly assigned to either reboxetine and celecoxib or to reboxetine plus placebo. After a wash-out period, 20 patients received 4-10 mg reboxetine plus placebo and 20 received reboxetine plus 400 mg celecoxib for 6 weeks. The treatment effect was calculated by analysis of variance. There were no significant differences between groups in age, sex, duration or severity of disease or psychopathology, or reboxetine dose or plasma levels. Over 6 weeks, both groups of patients showed significant improvement in scores of the Hamilton Depression Scale. However, the celecoxib group showed significantly greater improvement compared to the reboxetine-alone group. Additional treatment with celecoxib has significant positive effects on the therapeutic action of reboxetine with regard to depressive symptomatology. Moreover, the fact that treatment with an anti-inflammatory drug showed beneficial effects on MD indicates that inflammation is related to the pathomechanism of the disorder, although the exact mechanisms remain to become elucidated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients in the reboxetine plus celecoxib group exhibited reductions in depression severity that were nearly twice as great (55% reduction) as those experienced by patients in the control group (33% reduction).”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“75% of patients receiving reboxetine plus celecoxib were categorized as responders, compared to only 45% of patients receiving reboxetine plus placebo”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“TNFα antagonists such as etanercept or infliximab and the COX-2 inhibitor celecoxib have all been found to alleviate depressive symptoms in double-blind, randomized, placebo-controlled studies”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“One study found positive effects on mood in medically healthy, major depressed patients.52”
From Association of depressive disorders, depression characteristics and antidepressant medication with inflammation (2012) · cites this paper as [52]
In the citing paper
“from the administration of COX2 inhibitors to patients with major depression81”
From From inflammation to sickness and depression: when the immune system subjugates the brain (2008) · cites this paper as [81]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The global burden of disease, 1990–2020
Lopez, A. D., & Murray, C. C. J. L. (1998) · Nature Medicine · doi:10.1038/3218 · Cited by 1,614
Cytokine-induced sickness behavior: where do we stand?
Dantzer, R. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0613 · Cited by 862
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735
Maes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E., & Neels, H. (1997) · Cytokine · doi:10.1006/cyto.1997.0238 · Cited by 728
Maes, M., Scharpé, S., Meltzer, H. Y., Bosmans, E., Suy, E., Calabrese, J., & Cosyns, P. (1993) · Psychiatry Research · doi:10.1016/0165-1781(93)90027-e · Cited by 439
Müller, N., Riedel, M., Scheppach, C., Brandstätter, B., Sokullu, S., Krampe, K., Ulmschneider, M., Engel, R. R., Möller, H.-J., & Schwarz, M. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1029 · Cited by 388
Self-citationFrommberger, U. H., Bauer, J., Haselbauer, P., Fräulin, A., Riemann, D., & Berger, M. (1997) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02900219 · Cited by 362
Capuron, L., Ravaud, A., Miller, A. H., & Dantzer, R. (2004) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2003.11.004 · Cited by 236
Song, C., Lin, A., Bonaccorso, S., Heide, C., Verkerk, R., Kenis, G., Bosmans, E., Scharpe, S., Whelan, A., Cosyns, P., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00025-1 · Cited by 232
Cited by
Items 101–200 of 802
The Role of BDNF in the Neuroimmune Axis Regulation of Mood Disorders
Jin, Y., Sun, L. H., Yang, W., Cui, R. J., & Xu, S. B. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00515 · Cited by 198
Impact of pain on the course of depressive and anxiety disorders
Gerrits, M. M. J. G., Vogelzangs, N., van Oppen, P., van Marwijk, H. W. J., van der Horst, H., & Penninx, B. W. J. H. (2012) · Pain · doi:10.1016/j.pain.2011.11.001 · Cited by 199
The role of the immune system in posttraumatic stress disorder
Katrinli, S., Oliveira, N. C. S., Felger, J. C., Michopoulos, V., & Smith, A. K. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02094-7 · Cited by 175
Peripheral Markers of Depression
Nobis, A., Zalewski, D., & Waszkiewicz, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123793 · Cited by 197
Ferreira Mello, B. S., Monte, A. S., McIntyre, R. S., Soczynska, J. K., Custódio, C. S., Cordeiro, R. C., Chaves, J. H., Mendes Vasconcelos, S. M., Nobre Júnior, H. V., Florenço de Sousa, F. C., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.06.008 · Cited by 195
“, 2006), celecoxib (Muller et al., 2006) and etanercept (Tyring et al.”
BackgroundNovel therapeutic targets in depression: Minocycline as a candidate treatment
Soczynska, J. K., Mansur, R. B., Brietzke, E., Swardfager, W., Kennedy, S. H., Woldeyohannes, H. O., Powell, A. M., Manierka, M. S., & McIntyre, R. S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.07.026 · Cited by 189
Dash, S., Syed, Y. A., & Khan, M. R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.880544 · Cited by 171
The biology of depression in cancer and the relationship between depression and cancer progression
Sotelo, J. L., Musselman, D., & Nemeroff, C. (2014) · International Review of Psychiatry · doi:10.3109/09540261.2013.875891 · Cited by 179
Assessment of sleep health in patients with rheumatic disease
Taylor-Gjevre, R., Gjevre, J. A., Skomro, R., & Nair, B. V. (2011) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.11.6 · Cited by 187
“Also, in a randomized trial, depressed patients who received the selective COX-2 inhibitor, celecoxib, in combination with reboxetine demonstrated fewer depressive symptoms compared with patients receiving reboxetine and placebo [94].”
Moylan, S., Jacka, F. N., Pasco, J. A., & Berk, M. (2013) · Brain and Behavior · doi:10.1002/brb3.137 · Cited by 186
“In addition, inhibition of COX2 has been shown in animal models to prevent anxiety development (Casolini et al. 2002), and celecoxib, a COX-2 inhibitor, has shown benefit as an augmentation agent to SSRIs in depression (Muller et al. 2006).”
BackgroundDepression in patients with rheumatoid arthritis: description, causes and mechanisms
Margaretten, M., Julian, L., Katz, P., & Yelin, E. (2011) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.11.62 · Cited by 183
Depression, comorbidities and the TNF-α system
Himmerich, H., Fulda, S., Linseisen, J., Seiler, H., Wolfram, G., Himmerich, S., Gedrich, K., Kloiber, S., Lucae, S., Ising, M., et al. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.03.013 · Cited by 181
Na, K.-S., Lee, K. J., Lee, J. S., Cho, Y. S., & Jung, H.-Y. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.09.006 · Cited by 176
p11 and its role in depression and therapeutic responses to antidepressants
Svenningsson, P., Kim, Y., Warner-Schmidt, J., Oh, Y.-S., & Greengard, P. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3564 · Cited by 174
A critical review of human endotoxin administration as an experimental paradigm of depression.
DellaGioia, N., & Hannestad, J. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.07.014 · Cited by 175
“In depressed patients who had not remitted with the antidepressant reboxetine, augmentation with the cyclooxygenase-2 (COX-2) inhibitor celecoxib, which blocks the conversion of arachidonic acid into inflammatory molecules called prostanoids, was superior to placebo (Muller et al., 2006).”
BackgroundFond, G., Hamdani, N., Kapczinski, F., Boukouaci, W., Drancourt, N., Dargel, A., Oliveira, J., Le Guen, E., Marlinge, E., Tamouza, R., et al. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12211 · Cited by 174
Song, C., Zhang, X. Y., & Manku, M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3569-08.2009 · Cited by 169
Immunology of Major Depression
Müller, N. (2014) · Neuroimmunomodulation · doi:10.1159/000356540 · Cited by 174
Self-citationPhenotypes, Risk Factors, and Mechanisms of Adult‐Onset Asthma
Ilmarinen, P., Tuomisto, L. E., & Kankaanranta, H. (2015) · Mediators of Inflammation · doi:10.1155/2015/514868 · Cited by 164
Peripheral administration of lactate produces antidepressant-like effects
Carrard, A., Elsayed, M., Margineanu, M., Boury-Jamot, B., Fragnière, L., Meylan, E. M., Petit, J.-M., Fiumelli, H., Magistretti, P. J., & Martin, J.-L. (2018) · Molecular Psychiatry · doi:10.1038/mp.2016.179 · Cited by 167
The role of depressive subtypes within the neuroinflammation hypothesis of major depressive disorder
Woelfer, M., Kasties, V., Kahlfuss, S., & Walter, M. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2018.03.034 · Cited by 171
Capuron, L., Fornwalt, F. B., Knight, B. T., Harvey, P. D., Ninan, P. T., & Miller, A. H. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.02.017 · Cited by 164
Klawonn, A. M., Fritz, M., Castany, S., Pignatelli, M., Canal, C., Similä, F., Tejeda, H. A., Levinsson, J., Jaarola, M., Jakobsson, J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2020.12.016 · Cited by 167
Therapeutic Strategies for Treatment of Inflammation-related Depression
Adzic, M., Brkic, Z., Mitic, M., Francija, E., Jovicic, M. J., Radulovic, J., & Maric, N. P. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170828163048 · Cited by 156
Kim, Y., & Won, E. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.04.020 · Cited by 169
Drexhage, R. C., van der Heul-Nieuwenhuijsen, L., Padmos, R. C., van Beveren, N., Cohen, D., Versnel, M. A., Nolen, W. A., & Drexhage, H. A. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000799 · Cited by 134
Cytokines as biomarkers in depressive disorder: current standing and prospects
Lichtblau, N., Schmidt, F. M., Schumann, R., Kirkby, K. C., & Himmerich, H. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.813442 · Cited by 155
Sepanjnia, K., Modabbernia, A., Ashrafi, M., Modabbernia, M.-J., & Akhondzadeh, S. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.58 · Cited by 153
Haroon, E., & Miller, A. H. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_40 · Cited by 153
Wager-Smith, K., & Markou, A. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.09.010 · Cited by 151
Therapeutic Implications of Brain–Immune Interactions: Treatment in Translation
Miller, A. H., Haroon, E., & Felger, J. C. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.167 · Cited by 152
Husain, M. I., Chaudhry, I. B., Husain, N., Khoso, A. B., Rahman, R. R., Hamirani, M. M., Hodsoll, J., Qurashi, I., Deakin, J. F., & Young, A. H. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117724352 · Cited by 144
Lopresti, A. L., Hood, S. D., & Drummond, P. D. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112458732 · Cited by 151
Associations between Melatonin, Neuroinflammation, and Brain Alterations in Depression
Won, E., Na, K., & Kim, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010305 · Cited by 160
Guo, J.-Y., Li, C.-Y., Ruan, Y.-P., Sun, M., Qi, X.-L., Zhao, B.-S., & Luo, F. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.03.076 · Cited by 148
“Clinical trails reported that adjunctive COX-2 inhibition with celecoxib is beneficial in treating depression (Muller et al., 2006; Nery et al., 2008).”
BackgroundSchizophrenia and inflammation research: a bibliometric analysis
Sun, H.-L., Bai, W., Li, X.-H., Huang, H., Cui, X.-L., Cheung, T., Su, Z.-H., Yuan, Z., Ng, C. H., & Xiang, Y.-T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.907851 · Cited by 148
“Among the 10 most cited articles, two articles were reviews on the pathology under SCZ and inflammation (51, 52), and another two articles focused on the treatment of psychiatric disorders (53, 54).”
BackgroundAsadabadi, M., Mohammadi, M.-R., Ghanizadeh, A. J., Modabbernia, A., Ashrafi, M., Hassanzadeh, E., Forghani, S., & Akhondzadeh, S. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2796-8 · Cited by 153
Oxidative/Nitrosative Stress and Immuno-inflammatory Pathways in Depression: Treatment Implications
Anderson, G., & Maes, M. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660738 · Cited by 147
Inflammation in depression: is adiposity a cause?
C. Shelton, R., & H. Miller, A. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.1/rshelton · Cited by 141
Gałecki, P., Gałecka, E., Maes, M., Chamielec, M., Orzechowska, A., Bobińska, K., Lewiński, A., & Szemraj, J. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.016 · Cited by 141
“, 2008) and might explain the effectiveness of COX-2 inhibitors in depression treatment (Müller et al., 2006).”
BackgroundRisperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial
Mahmoud, R. A., Pandina, G. J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C. M., Kujawa, M. J., & Gharabawi-Garibaldi, G. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00003 · Cited by 140
“These strategies include switching monotherapy within (10, 16–18) or between antidepressant classes (10, 19–21), combination regimens consisting of 2 antidepressants (22–26), and “augmentation” of antidepressants with nonstandard treatments—for example, thyroid hormone (27); S-adenosyl-L-methionine (28); lithium (29);…”
BackgroundThe role of mitochondria in mood disorders: from physiology to pathophysiology and to treatment
Giménez-Palomo, A., Dodd, S., Anmella, G., Carvalho, A. F., Scaini, G., Quevedo, J., Pacchiarotti, I., Vieta, E., & Berk, M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.546801 · Cited by 140
“Antidepressants also increase autophagy and neural plasticity (134, 258).”
BackgroundAnti-inflammatory treatments for mood disorders: Systematic review and meta-analysis
Husain, M. I., Strawbridge, R., Stokes, P. R., & Young, A. H. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725711 · Cited by 139
Pro-inflammatory biomakers in depression: Treatment with venlafaxine
Piletz, J. E., Halaris, A., Iqbal, O., Hoppensteadt, D., Fareed, J., Zhu, H., Sinacore, J., & DeVane, C. L. (2009) · The World Journal of Biological Psychiatry · doi:10.3109/15622970802573246 · Cited by 130
Inflammation, Heart Disease, and Depression
Halaris, A. E. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0400-5 · Cited by 148
Tanaka, K., Furuyashiki, T., Kitaoka, S., Senzai, Y., Imoto, Y., Segi-Nishida, E., Deguchi, Y., Breyer, R. M., Breyer, M. D., & Narumiya, S. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5952-11.2012 · Cited by 131
The renin–angiotensin system: a possible new target for depression
Vian, J., Pereira, C., Chavarria, V., Köhler, C., Stubbs, B., Quevedo, J., Kim, S.-W., Carvalho, A. F., Berk, M., & Fernandes, B. S. (2017) · BMC Medicine · doi:10.1186/s12916-017-0916-3 · Cited by 134
The Microbiota-Inflammasome Hypothesis of Major Depression
Inserra, A., Rogers, G. B., Licinio, J., & Wong, M. (2018) · BioEssays · doi:10.1002/bies.201800027 · Cited by 134
Inflammation-induced depression: Its pathophysiology and therapeutic implications
Jeon, S. W., & Kim, Y.-K. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.10.016 · Cited by 134
Vogelzangs, N., Beekman, A. T., van Reedt Dortland, A. K., Schoevers, R. A., Giltay, E. J., de Jonge, P., & Penninx, B. W. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.9 · Cited by 133
“One study found positive effects on mood in medically healthy, major depressed patients (Muller et al, 2006).”
BackgroundNovel neuroimmunologic therapeutics in depression: A clinical perspective on what we know so far
Roman, M., & Irwin, M. R. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.09.016 · Cited by 132
“Thus, this study demonstrated that reboxetine plus celecoxib treatment was superior to reboxetine alone with regards to improving depressive symptoms (Muller et al., 2006).”
BackgroundResultCattaneo, A., Ferrari, C., Uher, R., Bocchio-Chiavetto, L., Riva, M. A., the MRC ImmunoPsychiatry Consortium, & Pariante, C. M. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw045 · Cited by 132
Leonard, B. E. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.10.018 · Cited by 129
Musil, R., Schwarz, M., Riedel, M. J., Dehning, S., Cerovecki, A., Spellmann, I., Arolt, V., & Müller, N. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.05.047 · Cited by 131
Self-citationDepression as a Risk Factor for Cancer: From Pathophysiological Advances to Treatment Implications
Currier, M. B., & Nemeroff, C. B. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-061212-171507 · Cited by 126
Inflammatory Biomarkers and Depression
Müller, N., Myint, A.-M., & Schwarz, M. (2010) · Neurotoxicity Research · doi:10.1007/s12640-010-9210-2 · Cited by 144
Self-citationThe hygiene hypothesis and psychiatric disorders
Rook, G. A. W., & Lowry, C. A. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.01.002 · Cited by 141
A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression
Eyre, H. A., Air, T., Proctor, S. J., Rositano, S., & Baune, B. T. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.10.003 · Cited by 132
Neuroinflammation as an etiological trigger for depression comorbid with inflammatory bowel disease
Craig, C. F., Filippone, R. T., Stavely, R., Bornstein, J. C., Apostolopoulos, V., & Nurgali, K. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02354-1 · Cited by 124
Gałecki, P., Szemraj, J., Bieńkiewicz, M., Zboralski, K., & Gałecka, E. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1014 · Cited by 124
Psychological Factors in Asthma
Van Lieshout, R. J., & MacQueen, G. (2008) · Allergy, Asthma & Clinical Immunology · doi:10.1186/1710-1492-4-1-12 · Cited by 118
The role of neuroinflammation and neurovascular dysfunction in major depressive disorder
Jeon, S. W., & Kim, Y.-K. (2018) · Journal of Inflammation Research · doi:10.2147/jir.s141033 · Cited by 118
Müller, N., & Schwarz, M. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-2012-3 · Cited by 140
Self-citationTowards an understanding of fatigue in Parkinson disease
Hagell, P., & Brundin, L. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.159772 · Cited by 120
ŞAHİN, T. D., Karson, A., Balcı, F., Yazır, Y., Bayramgürler, D., & Utkan, T. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.05.062 · Cited by 130
Posttraumatic stress disorder: does the gut microbiome hold the key?
Leclercq, S., Forsythe, P., & Bienenstock, J. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716635535 · Cited by 121
“A double-blind, randomized, placebo-controlled clinical trial showed that addition of a COX-2 inhibitor to standard antidepressant therapy induced a greater improvement of depressive symptoms than antidepressant alone.(36) However, the trial consisted of a small number of patients and has yet to be replicated in a lar…”
MethodHermanson, D. J., Gamble-George, J. C., Marnett, L. J., & Patel, S. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.04.006 · Cited by 121
Müller, N. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00375 · Cited by 115
Self-citationAmirani, E., Milajerdi, A., Mirzaei, H., Jamilian, H., Mansournia, M. A., Hallajzadeh, J., & Ghaderi, A. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2020.102361 · Cited by 113
Taler, M., Gil‐Ad, I., Lomnitski, L., Korov, I., Baharav, E., Bar, M., Zolokov, A., & Weizman, A. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.03.010 · Cited by 127
Treatment response and cognitive impairment in major depression: Association with C-reactive protein
Chang, H. H., Lee, I. H., Gean, P. W., Lee, S.-Y., Chi, M. H., Yang, Y. K., Lu, R.-B., & Chen, P. S. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.07.239 · Cited by 120
Pain and affective distress in arthritis: relationship to immunity and inflammation
Harth, M., & Nielson, W. R. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1573675 · Cited by 133
Lasselin, J., Lekander, M., Benson, S., Schedlowski, M., & Engler, H. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00869-2 · Cited by 114
Carniel, B. P., & da Rocha, N. S. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110151 · Cited by 127
A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase
Davies, Christmas, D., & Potokar, J. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s17573 · Cited by 119
Mode of action of mood stabilizers: is the arachidonic acid cascade a common target?
Rao, J. S., Lee, H.-J., Рапопорт, С. И., & Bazinet, R. P. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.31 · Cited by 137
Kashani, L., Omidvar, T., Farazmand, B., Modabbernia, A., Ramzanzadeh, F., Tehraninejad, E. S., Ashrafi, M., Tabrizi, M., & Akhondzadeh, S. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.08.010 · Cited by 116
Principles of inflammasome priming and inhibition: implications for psychiatric disorders
Herman, F. J., & Pasinetti, G. M. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.06.010 · Cited by 115
The Interface of Pain and Mood Disturbances in the Rheumatic Diseases
Goldenberg, D. L. (2009) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.11.005 · Cited by 131
Impact of antidepressants on cytokine production of depressed patients in Vitro
Munzer, A., Sack, U., Mergl, R., Schönherr, J., Petersein, C., Bartsch, S., Kirkby, K., Bauer, K., & Himmerich, H. (2013) · Toxins · doi:10.3390/toxins5112227 · Cited by 114
“A significant therapeutic effect of celecoxib in major depression was also found in a randomized, double-blind pilot add-on study of reboxetine and celecoxib versus reboxetine and placebo [20].”
BackgroundMalaise, melancholia and madness: The evolutionary legacy of an inflammatory bias
Raison, C. L., & Miller, A. H. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.04.009 · Cited by 110
Evidence for Inflammation-Associated Depression
Liu, C. S., Adibfar, A., Herrmann, N., Gallagher, D., & Lanctôt, K. L. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_2 · Cited by 123
Chronic dim light at night provokes reversible depression-like phenotype: possible role for TNF
Bedrosian, T. A., Weil, Z. M., & Nelson, R. J. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.96 · Cited by 112
Anti-TNF-α Compounds as a Treatment for Depression
Uzzan, S., & Azab, A. N. (2021) · Molecules · doi:10.3390/molecules26082368 · Cited by 126
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
McNamara, R. K., & Lotrich, F. E. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.98 · Cited by 108
The Developing Microbiome From Birth to 3 Years: The Gut-Brain Axis and Neurodevelopmental Outcomes
Laue, H. E., Coker, M. O., & Madan, J. C. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.815885 · Cited by 120
Le‐Niculescu, H., McFarland, M. J., Ogden, C. A., Balaraman, Y., Patel, S., Tan, J., Rodd, Z. A., Paulus, M., Geyer, M. A., Edenberg, H. J., et al. (2008) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30707 · Cited by 111
Telleria-Diaz, A., Schmidt, M., Kreusch, S., Neubert, A.-K., Schache, F., Vazquez, E., Vanegas, H., Schaible, H.-G., & Ebersberger, A. (2010) · Pain · doi:10.1016/j.pain.2009.08.013 · Cited by 109
Myint, A. M., Steinbusch, H. W. M., Goeghegan, L., Luchtman, D., Kim, Y. K., & Leonard, B. E. (2007) · Neuroimmunomodulation · doi:10.1159/000107420 · Cited by 109
The role of the kynurenine metabolism in major depression
Myint, A.-M., Schwarz, M., & Müller, N. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0741-3 · Cited by 126
Self-citationImmunity, Inflammation, and Bipolar Disorder: Diagnostic and Therapeutic Implications
Hamdani, N., Doukhan, R., Kurtlucan, O., Tamouza, R., & Leboyer, M. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0387-y · Cited by 119
Inflammation as a treatment target in mood disorders: review
Jones, B. D. M., Daskalakis, Z. J., Carvalho, A. F., Strawbridge, R., Young, A. H., Mulsant, B. H., & Husain, M. I. (2020) · BJPsych Open · doi:10.1192/bjo.2020.43 · Cited by 106
“Table 1 Identified clinical trials of anti-inflammatory agents in major depressive disorder (MDD) Reference Number of patients Comorbidity/ enriched sample Diagnosis Treatment arms Duration Results Randomised Analysed Active Placebo NSAIDs Müller et al (2006)59 40 18 None/No MDD, DSM-IV NARI + celecoxib 400 mg o.d. (n…”
BackgroundInfluentialNSAIDs Are Associated with Lower Depression Scores in Patients with Osteoarthritis
Iyengar, R. L., Gandhi, S., Aneja, A., Thorpe, K. E., Razzouk, L., Greenberg, J., Mosovich, S., & Farkouh, M. E. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.02.037 · Cited by 117
Molteni, R., Macchi, F., Zecchillo, C., Dell’Agli, M., Colombo, E., Calabrese, F., Guidotti, G., Racagni, G., & Riva, M. A. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.03.008 · Cited by 112
Van Lieshout, R. J., Bienenstock, J., & MacQueen, G. M. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907012 · Cited by 102
Faster, better, stronger: Towards new antidepressant therapeutic strategies
O’Leary, O. F., Dinan, T. G., & Cryan, J. F. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.046 · Cited by 115
Maes, M., Leonard, B., Fernandez, A., Kubera, M., Nowak, G., Veerhuis, R., Gardner, A., Ruckoanich, P., Geffard, M., Altamura, C., et al. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.02.019 · Cited by 100
Tang, J., Yu, W., Chen, S., Gao, Z., & Xiao, B. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2504-0 · Cited by 104
Vancassel, S., Capuron, L., & Castanon, N. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00499 · Cited by 94
Metadata
- Authors
- Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., Möller, H.-J., Arolt, V, & Riedel, M.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- University of Münster (DE)
- Corresponding author
- Müller, N
- Venue
- Molecular Psychiatry
- Published
- 2006-02-21
- Volume
- 11
- Issue
- 7
- Pages
- 680-684
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2049808835
- Cited by
- 794
- References
- 37
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 24 · 2023: 30 · 2022: 42 · 2021: 42 · 2020: 37 · 2019: 44 · 2018: 52 · 2017: 45 · 2016: 42 · 2015: 54 · 2014: 53 · 2013: 61 · 2012: 50
- FWCI
- 20.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- celecoxib, COX-2 inhibitors, major depressive disorder, reboxetine, anti-inflammatory therapy, inflammatory cytokines, prostaglandin E2, adjunctive therapy, acute depressive episode
- MeSH terms
- Celecoxib, Reboxetine, Adult, Antidepressive Agents, Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Inflammation, Lorazepam, Male, Middle Aged, Morpholines, Patient Dropouts, Pilot Projects, Psychological Tests, Pyrazoles, Serotonin, Severity of Illness Index, Sulfonamides, Anti-Anxiety Agents, Dinoprostone, Interleukin-6, Adrenergic Uptake Inhibitors, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.